Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia

OncoImmunology

Volumn 5, Issue 9, 2016, Pages

  Vyas, Maulik ^a   Schneider, Ann Charlott ^a   Shatnyeva, Olga ^a   Reiners, Katrin S ^a   Tawadros, Samir ^a   Kloess, Stephan ^b   Köhl, Ulrike ^b   Hallek, Michael ^a   Hansen, Hinrich P ^a   Pogge von Strandmann, Elke ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CD19; CLL; immunoligand; NK cells; NKG2D; triplebody; ULBP2

Indexed keywords

ALLOANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; UL16 BINDING PROTEIN 2; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 84984677230     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1211220     Document Type: Article

References (50)

1. O.M.Shatnyeva, H.P.Hansen, K.S.Reiners, M.Sauer, M.Vyas, E.P.von Strandmann. DNA damage response and evasion from immunosurveillance in CLL:new options for NK cell-based immunotherapies. Front Genet 2015; 6:11; PMID:25699074; http://dx.doi.org/10.3389/fgene.2015.00011
2. M.Le Garff-Tavernier, J.Decocq, C.de Romeuf, C.Parizot, C.A.Dutertre, E.Chapiro, F.Davi, P.Debré, J.F.Prost, J.L.Teillaud et al. Analysis of CD16+CD56dim NK cells from CLL patients:evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2011; 25:101-9; PMID:20975664; http://dx.doi.org/10.1038/leu.2010.240
3. H.Guven, M.Gilljam, B.J.Chambers, H.G.Ljunggren, B.Christensson, E.Kimby, M.S.Dilber. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL):a potential source for cellular immunotherapy. Leukemia 2003; 17:1973-80; PMID:14513047; http://dx.doi.org/10.1038/sj.leu.2403083
4. M.Gentile, E.Vigna, C.Mazzone, E.Lucia, A.Recchia, L.Morabito, M.Bisconte, C.Gentile, F.Morabito. Rituximab for the treatment of patients with chronic lymphocytic leukemia. Cancer Manag Res 2010; 2:71-81; PMID:21188098; http://dx.doi.org/10.2147/CMAR.S5621
5. C.Veuillen, T.Aurran-Schleinitz, R.Castellano, J.Rey, F.Mallet, F.Orlanducci, L.Pouyet, S.Just-Landi, D.Coso, V.Ivanov et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2012; 32:632-46; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
6. G.Maki, G.M.Hayes, A.Naji, T.Tyler, E.D.Carosella, N.Rouas-Freiss, S.A.Gregory. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients:implication of HLA-G. Leukemia 2008; 22:998-1006; PMID:18288133; http://dx.doi.org/10.1038/leu.2008.15
7. A.Gismondi, H.Stabile, P.Nisti, A.Santoni. Effector functions of natural killer cell subsets in the control of hematological malignancies. Front Immunol 2015; 6:567; PMID:26594216; http://dx.doi.org/10.3389/fimmu.2015.00567
8. L.L.Lanier. Up on the tightrope:natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
9. S.Bauer, V.Groh, J.Wu, A.Steinle, J.H.Phillips, L.L.Lanier, T.Spies. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-9; PMID:10426993; http://dx.doi.org/10.1126/science.285.5428.727
10. H.Das, V.Groh, C.Kuijl, M.Sugita, C.T.Morita, T.Spies, J.F.Bukowski. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15:83-93; PMID:11485740; http://dx.doi.org/10.1016/S1074-7613(01)00168-6
11. D.H.Raulet. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3:781-90; PMID:14523385; http://dx.doi.org/10.1038/nri1199
12. E.Laprevotte, G.Voisin, L.Ysebaert, C.Klein, C.Daugrois, G.Laurent, J.J.Fournie, A.Quillet-Mary. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 2013; 191:3634-40; PMID:23997218; http://dx.doi.org/10.4049/jimmunol.1300187
13. K.S.Reiners, D.Topolar, A.Henke, V.R.Simhadri, J.Kessler, M.Sauer, M.Bessler, H.P.Hansen, S.Tawadros, M.Herling et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013; 121:3658-65; PMID:23509156; http://dx.doi.org/10.1182/blood-2013-01-476606
14. H.Nuckel, M.Switala, L.Sellmann, P.A.Horn, J.Durig, U.Duhrsen, R.Küppers, H.Grosse-Wilde, V.Rebmann. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:1152-9; PMID:20428196; http://dx.doi.org/10.1038/leu.2010.74
15. L.Ysebaert, E.Gross, E.Kuhlein, A.Blanc, J.Corre, J.J.Fournie, G.Laurent, A.Quillet-Mary. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia:implication for maintenance immunotherapy. Leukemia 2010; 24:1310-6; PMID:20463751; http://dx.doi.org/10.1038/leu.2010.89
16. S.M.O'Brien, H.Kantarjian, D.A.Thomas, F.J.Giles, E.J.Freireich, J.Cortes, S.Lerner, M.J.Keating. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-70; PMID:11304768
17. S.A.Beers, R.R.French, H.T.Chan, S.H.Lim, T.C.Jarrett, R.M.Vidal, S.S.Wijayaweera, S.V.Dixon, H.Kim, K.L.Cox et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies:implications for antibody selection. Blood 2010; 115:5191-201; PMID:20223920; http://dx.doi.org/10.1182/blood-2010-01-263533
18. P.V.Beum, A.D.Kennedy, M.E.Williams, M.A.Lindorfer, R.P.Taylor. The shaving reaction:rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176:2600-9; PMID:16456022; http://dx.doi.org/10.4049/jimmunol.176.4.2600
19. M.Vyas, U.Koehl, M.Hallek, E.P.von Strandmann. Natural ligands and antibody-based fusion proteins:harnessing the immune system against cancer. Trends Mol Med 2014; 20:72-82; PMID:24268686; http://dx.doi.org/10.1016/j.molmed.2013.10.006
20. E.P.von Strandmann, H.P.Hansen, K.S.Reiners, R.Schnell, P.Borchmann, S.Merkert, V.R.Simhadri, A.Draube, M.Reiser, I.Purr et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107:1955-62; PMID:16210338; http://dx.doi.org/10.1182/blood-2005-05-2177
21. A.Rothe, R.D.Jachimowicz, S.Borchmann, M.Madlener, J.Kessler, K.S.Reiners, M.Sauer, H.P.Hansen, R.T.Ullrich, S.Chatterjee et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer 2014; 134:2829-40; PMID:24242212; http://dx.doi.org/10.1002/ijc.28609
22. R.D.Jachimowicz, G.Fracasso, P.J.Yazaki, B.E.Power, P.Borchmann, A.Engert, H.P.Hansen, K.S.Reiners, M.Marie, E.P.von Strandmann et al. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther 2011; 10:1036-45; PMID:21525185; http://dx.doi.org/10.1158/1535-7163.MCT-10-1093
23. C.Kellner, A.Gunther, A.Humpe, R.Repp, K.Klausz, S.Derer, T.Valerius, M.Ritgen, M.Brüggemann, J.G.van de Winkel et al. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology 2016; 5:e1058459; PMID:26942070; http://dx.doi.org/10.1080/2162402X.2015.1058459
24. C.Kellner, T.Maurer, D.Hallack, R.Repp, J.G.van de Winkel, P.W.Parren, T.Valerius, A.Humpe, M.Gramatzki, M.Peipp. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol 2012; 189:5037-46; PMID:23066150; http://dx.doi.org/10.4049/jimmunol.1201321
25. M.Peipp, S.Derer, S.Lohse, M.Staudinger, K.Klausz, T.Valerius, M.Gramatzki, C.Kellner. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget 2015; 6:32075-88; PMID:26392331; http://dx.doi.org/10.18632/oncotarget.5135
26. I.Schubert, D.Saul, S.Nowecki, A.Mackensen, G.H.Fey, F.S.Oduncu. A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs 2014; 6:286-96; PMID:24135631; http://dx.doi.org/10.4161/mabs.26768
27. I.Schubert, C.Kellner, C.Stein, M.Kugler, M.Schwenkert, D.Saul, K.Mentz, H.Singer, B.Stockmeyer, W.Hillen et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3:21-30; PMID:21081841; http://dx.doi.org/10.4161/mabs.3.1.14057
28. M.Kugler, C.Stein, C.Kellner, K.Mentz, D.Saul, M.Schwenkert, I.Schubert, H.Singer, F.Oduncu, B.Stockmeyer et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150:574-86; PMID:20636437; http://dx.doi.org/10.1111/j.1365-2141.2010.08300.x
29. U.H.Weidle, G.Tiefenthaler, E.H.Weiss, G.Georges, U.Brinkmann. The intriguing options of multispecific antibody formats for treatment of cancer. Cancer Genom Proteom 2013; 10:1-18; PMID:23382582
30. J.D.Coudert, W.Held. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16:333-43; PMID:16914326; http://dx.doi.org/10.1016/j.semcancer.2006.07.008
31. T.Robak. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia:state of the art. Expert Rev Hematol 2014; 7:841-57; PMID:25249370; http://dx.doi.org/10.1586/17474086.2014.963048
32. C.Kellner, J.Bruenke, H.Horner, J.Schubert, M.Schwenkert, K.Mentz, K.Barbin, C.Stein, M.Peipp, B.Stockmeyer et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011; 303:128-39; PMID:21339041; http://dx.doi.org/10.1016/j.canlet.2011.01.020
33. C.L.Lorentzen, P.T.Straten. CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. Scand J Immunol 2015; 82:307-19; PMID:26099639; http://dx.doi.org/10.1111/sji.12331
34. M.J.Newman, D.J.Benani. A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Pract 2016; 22:639-45; PMID:26607163; http://dx.doi.org/10.1177/1078155215618770
35. C.Kellner, J.Bruenke, J.Stieglmaier, M.Schwemmlein, M.Schwenkert, H.Singer, K.Mentz, M.Peipp, P.Lang, F.Oduncu et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 2008; 31:871-84; PMID:18833000; http://dx.doi.org/10.1097/CJI.0b013e318186c8b4
36. A.Rayes, R.L.McMasters, M.M.O'Brien. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 2016; 63:1113-5; PMID:26914337; http://dx.doi.org/10.1002/pbc.25953
37. T.Horng, J.S.Bezbradica, R.Medzhitov. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007; 8:1345-52; PMID:17952078; http://dx.doi.org/10.1038/ni1524
38. C.Zhang, J.Zhang, J.Niu, J.Zhang, Z.Tian. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 2008; 42:128-36; PMID:18280748; http://dx.doi.org/10.1016/j.cyto.2008.01.003
39. D.Gogoi, S.V.Chiplunkar. Targeting gamma delta T cells for cancer immunotherapy:bench to bedside. Indian J Med Res 2013; 138:755-61; PMID:24434328
40. H.H.Oberg, C.Kellner, D.Gonnermann, M.Peipp, C.Peters, S.Sebens, D.Kabelitz, D.Wesch. Gammadelta T cell activation by bispecific antibodies. Cell Immunol 2015; 296:41-9; PMID:25979810; http://dx.doi.org/10.1016/j.cellimm.2015.04.009
41. H.H.Oberg, M.Peipp, C.Kellner, S.Sebens, S.Krause, D.Petrick, S.Adam-Klages, C.Röcken, T.Becker, I.Vogel et al. Novel bispecific antibodies increase gammadelta T-cell cytotoxicity against pancreatic cancer cells. Cancer Res 2014; 74:1349-60; PMID:24448235; http://dx.doi.org/10.1158/0008-5472.CAN-13-0675
42. A.Barber, C.L.Sentman. NKG2D receptor regulates human effector T-cell cytokine production. Blood 2011; 117:6571-81; PMID:21518928; http://dx.doi.org/10.1182/blood-2011-01-329417
43. J.L.Upshaw, P.J.Leibson. NKG2D-mediated activation of cytotoxic lymphocytes:unique signaling pathways and distinct functional outcomes. Semin Immunol 2006; 18:167-75; PMID:16723257; http://dx.doi.org/10.1016/j.smim.2006.03.001
44. K.Schroder, P.J.Hertzog, T.Ravasi, D.A.Hume. Interferon-gamma:an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-89; PMID:14525967; http://dx.doi.org/10.1189/jlb.0603252
45. O.Lim, M.Y.Jung, Y.K.Hwang, E.C.Shin. Present and future of allogeneic natural killer cell therapy. Front Immunol 2015; 6:286; PMID:26089823; http://dx.doi.org/10.3389/fimmu.2015.00286
46. A.P.Kater, M.H.van Oers, T.J.Kipps. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007; 110:2811-8; PMID:17638850; http://dx.doi.org/10.1182/blood-2007-01-068932
47. C.I.Dahlberg, D.Sarhan, M.Chrobok, A.D.Duru, E.Alici. Natural killer cell-based therapies targeting cancer:possible strategies to gain and sustain anti-tumor activity. Front Immunol 2015; 6:605; PMID:26648934; http://dx.doi.org/10.3389/fimmu.2015.00605
48. S.Carlens, M.Gilljam, B.J.Chambers, J.Aschan, H.Guven, H.G.Ljunggren, B.Christensson, M.S.Dilber. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001; 62:1092-8; PMID:11600215; http://dx.doi.org/10.1016/S0198-8859(01)00313-5
49. M.Cheng, Y.Chen, W.Xiao, R.Sun, Z.Tian. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http://dx.doi.org/10.1038/cmi.2013.10
50. M.Stocker, M.K.Tur, S.Sasse, A.Krussmann, S.Barth, A.Engert. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 2003; 28:211-9; PMID:12699683; http://dx.doi.org/10.1016/S1046-5928(02)00709-X